Posters

      In Vitro Toxicological Assessment Of Total Particulate Matter Of Tobacco Smoke And A pMRTP Aerosol In Human Lung Epithelial And Coronary Endothelial Cells

      Marescotti, D.; Gonzalez-Suarez, I.; Acali, S.; Johne, S. Johne.; Mathis, C.; Frentzel, S.; Walker, P.; Ellis, S.; Woodhouse, H.; De Leon, H.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Mar 23, 2014
      Conference name
      Society of Toxicology (SOT) 2014
      Link to more information
      Link to more information
      Topic
      Summary

      Cigarette smoke (CS) is a risk factor for cardiovascular and chronic obstructive pulmonary disease diseases. Being a complex aerosol with over 6,000 chemicals, it is difficult to determine the contribution of individual constituents to overall CS toxicity. The biological impact of total particulate matter (TPM) from the reference cigarette 3R4F and prototypic modified risk tobacco products (MRTPs) was investigated in normal human bronchial epithelial (NHBE) and human coronary artery endothelial (HCAEC) cells, two cell types relevant to respiratory and vascular diseases. Using an impedance-based real-time cellular analysis system, we optimized the experimental conditions (e.g., dose-ranges and exposure times) for subsequent high content screening (HCS) analysis. Toxicological HCS assessment was conducted using seven multi-parametric indicators of cellular toxicity. In the case of 3R4F, the results showed a clear dose-response and cytotoxicity at doses of TPM above 100µg/ml. No effects were observed for the TPM from prototypic MRTPs. Furthermore, HCAEC appeared to be more sensitive than NHBE cells in their response to TPM. The combination of impedance-based and HCS technologies provides a robust scientific basis for in vitro systems biology-based risk assessment for MRTPs. 

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.